A new discovery may one day lead to natural anticavity products, researchers report. The scientists from West China School of Stomatology and Academic Centre for Dentistry Amsterdam have figured out the main active ingredient of Galla Chinensis, a natural herb, and further improved its anti-caries efficacy. The finding is published in The Open Dentistry Journal. To...
Category: <span>Pharmaceutical Updates</span>
Post
Reversing opioid overdose: Concentrated naloxone nasal spray as good as injection
A new study published by the scientific journal Addiction has found that a concentrated 2mg intranasal naloxone spray delivers naloxone as effectively, over the critical first 15 minutes, as the standard 0.4mg intramuscular (IM) naloxone injection. The 2mg spray also maintains blood levels of naloxone more than twice as high as the 0.4mg IM levels for two...
Post
Discovery of a promising medication for amyotrophic lateral sclerosis
Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medication that could make it possible to treat individuals with amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. An article published today in JCI Insight concludes that pimozide was found to be...
Post
Study shows alectinib 600 mg more effective than crizotinib in Asian cancer patients
A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress. The J-ALEX study demonstrated that alectinib 300 mg twice daily...
Post
Brothers with rare terminal muscle disorder fear their future after the FDA denies the drug that keeps them walking
Elliot Johnson, 14, and Henry, 11, both suffer from Duchenne muscular dystrophy It is a rare form of the disease that causes muscle weakness, eventually leading to complete loss of mobility with a mortality rate of around 25 The brothers have been part of a clinical trial with a drug that has shown profound improvements and...
Post
Scientists are working to eliminate the causes of countless chronic and recurrent human infections
Before the discoveries that could lead to biofilm eradication, before the idea that he was even working on treatments for the bacterial communities that are crucial to most human infections, Steven Goodman, PhD, had a mystery on his hands. For nearly 15 years. Dr. Goodman, then a biochemist at the University of Southern California’s Herman Ostrow School of Dentistry, found a certain group of...
Post
Promising new drug for hepatitis B tested
Dr. Robert Lanford works in his lab at Texas Biomed. Research at the Southwest National Primate Research Center (SNPRC) on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection. Testing at SNPRC provided proof this novel therapeutic approach and drug...
Post
Scientists discover potential treatment to stop glaucoma in its tracks
Retinal ganglion cells (green) connecting with astrocytes (red) and blood cells (white) in the inner retina. Vision scientists at the University of California, Berkeley, and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, the world’s second-leading cause of blindness....
Post
Researcher draws bulls eye around muscular dystrophy drug targets
Francis M. Sverdrup, Ph.D., research fellow in the Saint Louis University Department of Biochemistry and Molecular Biology. In a recent paper published in the journal Skeletal Muscle, a Saint Louis University researcher reports success in identifying new drug targets that potentially could slow or halt the progression of a form muscular dystrophy, an illness characterized...
Post
Flavonoid derivatives targeting NF-kappaB
The aim of the study was to develop new synthetic anti-inflammatory and cytotoxic agents targeting NF-kappaB Nuclear factor-kappaB (NF-kappaB) has been reported to regulate various genes involved in cancer and inflammation. Accordingly, drugs inhibiting NF-kappaB may possess both anti-inflammatory and anticancer properties. So there is a need to discover novel compounds which should not only...